← Leaderboards
Joseph William Landry
Virginia Commonwealth University
$2,951,878
Attributed
$7,043,223
Total exposure
6
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.6M · FY2019–25$2M$1.5M$1M$500K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,043,223 · 6
By mechanism
R01$5,828,126 · 3
R21$1,215,097 · 3
Top collaborators
- David A. Gewirtz14 shared
- Hisashi Harada14 shared
- Swadesh K Das2 shared
- Paul B Fisher2 shared
- William Charles Krause Pomerantz2 shared
Most similar at Virginia Commonwealth University
Same institution · by research overlap
- Hisashi Harada$3,277,011
- David A. Gewirtz$3,700,163
- Paul B Fisher$21,846,479
- Devanand Sarkar$13,330,601
- Bin Gao$700,617
Others in their field
Other Emerging Leaders on “Immune”
- Bambra Strokes · Ppd Development Lp$526,656,217
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$181,310,675
- Kevin Urdahl · Seattle Children'S Hospital$84,741,409
- Ted Ross · University Of Georgia$74,507,826
- Yunda Huang · Fred Hutchinson Cancer Center$73,602,469
- Tony Moody · Duke University$66,767,417
Research focus
ImmuneTumorNeoplastic CellImmune SystemMalignant NeoplasmsCellsMediatingAnimalsDesignAnti-Tumor Immune ResponseCell Culture TechniquesMortalityMouse ModelGrowthPropertyChemotherapyResponseExperimental StudyCharacteristicsIn VitroClinical TrialsApoptoticPreventImmunogenic
Grant awards (22)
Modulating growth, progression and metastasis in breast cancer by inhibiting MDA-9$619,098
R01 · FY2025 · CA
A sequential therapeutic strategy of senescence induction and senolytics for elimination of surviving residual breast tumor cells$517,388
R01 · FY2025 · CA
Enhancing Tumor Cell Immunogenicity using Improved Molecules Targeting Chromatin Remodeling$181,332
R21 · FY2025 · CA · contact PI
Modulating growth, progression and metastasis in breast cancer by inhibiting MDA-9$622,329
R01 · FY2024 · CA
A sequential therapeutic strategy of senescence induction and senolytics for elimination of surviving residual breast tumor cells$491,519
R01 · FY2024 · CA
Enhancing Tumor Cell Immunogenicity using Improved Molecules Targeting Chromatin Remodeling$230,523
R21 · FY2024 · CA · contact PI
Development of Mouse and Humanized Models to Study Sex Disparities in Tumor Progression and Treatment of NSCLC$172,376
R21 · FY2024 · CA · contact PI
A sequential therapeutic strategy of senescence induction and senolytics for elimination of surviving residual breast tumor cells$45,933
R01 · FY2024 · CA
A sequential therapeutic strategy of senescence induction and senolytics for elimination of surviving residual breast tumor cells$499,191
R01 · FY2023 · CA
Use of senolytics to enhance chemotherapeutic efficacy in lung cancer$273,905
R01 · FY2023 · CA
Development of Mouse and Humanized Models to Study Sex Disparities in Tumor Progression and Treatment of NSCLC$217,738
R21 · FY2023 · CA · contact PI
Use of senolytics to enhance chemotherapeutic efficacy in lung cancer$66,687
R01 · FY2023 · CA
A sequential therapeutic strategy of senescence induction and senolytics for elimination of surviving residual breast tumor cells$43,892
R01 · FY2023 · CA
A sequential therapeutic strategy of senescence induction and senolytics for elimination of surviving residual breast tumor cells$499,191
R01 · FY2022 · CA
Use of senolytics to enhance chemotherapeutic efficacy in lung cancer$386,245
R01 · FY2022 · CA
Use of senolytics to enhance chemotherapeutic efficacy in lung cancer$56,404
R01 · FY2022 · CA
A sequential therapeutic strategy of senescence induction and senolytics for elimination of surviving residual breast tumor cells$509,377
R01 · FY2021 · CA
Use of senolytics to enhance chemotherapeutic efficacy in lung cancer$398,989
R01 · FY2021 · CA
Enhancing Breast Tumor Cell Immunogenicity by Targeting the Epigenetic Factor NURF$187,539
R21 · FY2021 · CA · contact PI
Use of senolytics to enhance chemotherapeutic efficacy in lung cancer$398,989
R01 · FY2020 · CA
Enhancing Breast Tumor Cell Immunogenicity by Targeting the Epigenetic Factor NURF$225,589
R21 · FY2020 · CA · contact PI
Use of senolytics to enhance chemotherapeutic efficacy in lung cancer$398,989
R01 · FY2019 · CA